Business Overview: LENZ Therapeutics, Inc. (NASDAQ: LENZ)

---

Executive Summary

LENZ Therapeutics is a commercial-stage ophthalmic pharmaceutical company based in San Diego, California, focused on a single mission: treating presbyopia, the age-related loss of near vision that affects nearly every adult over roughly age 45. Its lead and only approved product, VIZZ (aceclidine ophthalmic solution 1.44%), received FDA approval on July 31, 2025, and began shipping to patients in October 2025. LENZ describes VIZZ as the first and only aceclidine-based presbyopia treatment approved by the FDA.

The company matters because presbyopia is an enormous, almost universal condition with no pharmaceutical standard of care until the recent emergence of eye-drop "reading glasses in a bottle" products. LENZ's mechanistic bet is that aceclidine — a pupil-selective miotic — can deliver a longer duration of near-vision improvement than earlier entrants based on pilocarpine, while avoiding the myopic shift (blurred distance vision) that pilocarpine-class drops can cause. LENZ is still in the earliest stages of commercial ramp: VIZZ generated only $1.6 million in net product revenue in its first full quarter of sales, against a FY2025 net loss of $82.1 million, funded by a substantial cash and marketable-securities position.

---

1. Core Business Model & How They Work

LENZ makes money two ways: direct U.S. sales of VIZZ in the self-pay (non-reimbursed) market, and ex-U.S. licensing/distribution deals that generate upfront payments, milestones, and royalties. Because VIZZ is sold without third-party insurance reimbursement, the company's U.S. commercial strategy leans heavily on building physician trust and consumer demand directly.

 R&D / Clinical          U.S. Commercialization              Ex-U.S. Partners
 (aceclidine             (self-pay market)                    (licensing model)
  formulation)        ┌─────────────────────┐             ┌──────────────────────┐
       │               │  In-house sales      │             │ CORXEL (Greater China)│
       ▼               │  force (~15,000 ECPs)│             │ Lotus (S. Korea/SEA)  │
   FDA Approval ───────▶  + free in-office     │────────────▶ Théa (Canada)         │
   (Jul 2025)          │  sampling             │             │ Lunatus (Middle East) │
       │               │  + DTC "Make It       │             └──────────┬───────────┘
       ▼               │  VIZZable" campaign   │                        │
   VIZZ launch         │  + e-pharmacy/retail  │                        ▼
   (Oct 2025)          └──────────┬────────────┘            Upfront + milestone +
                                   ▼                          royalty payments to LENZ
                        Patient self-pay purchase

The U.S. sales organization has grown from 88 to a planned 117 territories, targeting the roughly 15,000 eye care professionals (optometrists and ophthalmologists) who can recommend or prescribe VIZZ, supplemented by free in-office samples, a direct-to-consumer "Make It VIZZable" marketing push, and distribution through both an e-pharmacy partner and traditional retail pharmacies.

---

2. Product Portfolio (Key Offerings)

---

3. Competitive Landscape

The presbyopia eye-drop category is young but increasingly crowded, splitting roughly into two mechanistic camps:

• Pilocarpine-class incumbents: Vuity (AbbVie/Allergan) was the first FDA-approved presbyopia drop and now faces generic Vuity competition, alongside Qlosi (Orasis Pharmaceuticals). These drops have an established prescriber base but carry known myopic-shift and dosing-frequency trade-offs that LENZ positions VIZZ against.
• Emerging aceclidine and next-generation entrants: Yuvezzi (FDA-approved January 2026) and pipeline programs from Tenpoint Therapeutics, AceVision, and Vyluma are pursuing similar or adjacent mechanisms, meaning LENZ's "first aceclidine approval" advantage has a closing window.
• Large-scale eye care and consumer health companies: Johnson & Johnson, Bausch & Lomb, Glaukos, Amneal, Eyenovia, Viatris, and OSRX Pharmaceuticals all have existing relationships with eye care professionals and far larger sales and marketing infrastructure than LENZ, and could out-market a differentiated but single-product competitor.

LENZ's relative position is as the clinically-differentiated specialist (longer duration, no myopic shift) competing against both an entrenched pilocarpine incumbent with scale (AbbVie) and a wave of fast-following aceclidine and next-gen mechanisms.

---

4. Strategic Strengths & Risks

Strengths:

• First-mover regulatory status as the only approved aceclidine-based presbyopia treatment, with patent protection around the formulation.
• Clinical differentiation — a mechanism designed to avoid the myopic shift that limits pilocarpine-based rivals, a real product-level advantage physicians can message to patients.
• Capital-light international expansion through licensing deals that bring in upfront and milestone cash without LENZ funding its own global salesforce.
• Strong balance sheet relative to burn — $292.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Risks:

• Single-product dependency. VIZZ is the company's only approved asset; any safety, pricing, or competitive setback hits the entire business.
• No insurance reimbursement. The self-pay model means consumer price sensitivity directly gates adoption, and there's no payer channel to fall back on.
• Early, small commercial ramp. VIZZ generated just $1.6 million in net product revenue in Q4 2025 against an $82.1 million full-year net loss — the company is far from proving the commercial model at scale.
• Competitive window closing. Yuvezzi's January 2026 approval and multiple aceclidine-class programs in development could erode LENZ's first-mover positioning before VIZZ reaches meaningful scale.
• Reliance on larger partners/competitors (AbbVie, J&J, Bausch & Lomb) who can out-invest LENZ in physician and consumer marketing.

---

5. Financial Overview

---

6. Summary Conclusion

LENZ Therapeutics is a focused, single-product bet on a genuinely differentiated mechanism in a presbyopia market that, until recently, had no pharmaceutical options at all. VIZZ's aceclidine chemistry gives LENZ a real, patent-protected clinical story — longer duration without the myopic shift that limits pilocarpine-class rivals — and its ex-U.S. licensing deals provide non-dilutive cash while the U.S. self-pay commercial engine is built out. The company's well-funded balance sheet ($292.3 million in cash and investments) buys time, but the biggest forward risk is competitive: Yuvezzi's approval and a wave of aceclidine and next-generation presbyopia programs from much larger companies (AbbVie, J&J, Bausch & Lomb) threaten to compress LENZ's first-mover window before VIZZ's still-nascent U.S. sales ($1.6 million in its first quarter) have scaled into a durable, profitable franchise.